Intravesical treatment of overactive bladder syndrome

被引:4
作者
Haferkamp A. [1 ,2 ]
Hohenfellner M. [1 ]
机构
[1] Urologische Klinik, Universitätsklinikum Heidelberg, Heidelberg
[2] Urologische Klinik, Universitätsklinikum Heidelberg, 69120 Heidelberg
来源
Der Urologe | 2006年 / 45卷 / 10期
关键词
Botulinum toxin; Capsaicin; Overactive bladder; Oxybutynin; Resiniferatoxin;
D O I
10.1007/s00120-006-1178-4
中图分类号
学科分类号
摘要
Overactive bladder and urgency incontinence are common conditions generally treated with oral anticholinergic medication. Despite the development of new antimuscarinic substances, many patients are refractory to or cannot tolerate the oral therapy due to severe side effects. Intravesical instillation therapy can provide an alternative method to manage detrusor overactivity. Intravesical instillation of anticholinergics such as oxybutynin and trospium chloride can achieve cholinergic blockade without producing systemic side effects. Botulinum toxin type A injections into the detrusor have been shown to increase bladder capacity and to decrease detrusor overactivity for 6 or more months. Intravesical local anesthetics such as lidocaine and bupivacaine block the conduction of unmyelinated C fibers which results in an increase of functional bladder capacity. Intravesical capsaicin and resiniferatoxin also affect the afferent C fiber innervation of the bladder, leading to a decrease in detrusor overactivity and also an increased bladder capacity. The use of intravesical anticholinergics and of local anesthetic medications, both known for their short-term efficacy, is limited due to the necessity of daily intermittent catheterization. In conclusion, intravesical therapies can provide an alternative treatment for the management of overactive bladder. © Springer Medizin Verlag 2006.
引用
收藏
页码:1283 / 1288
页数:5
相关论文
共 26 条
  • [1] Apostolidis A., Popat R., Yiangou Y., Et al., Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity, J Urol, 174, pp. 977-982, (2005)
  • [2] Brendler C.B., Radebaugh L.C., Mohler J.L., Topical oxybutynin chloride for relaxation of dysfunctional bladders, J Urol, 141, pp. 1350-1352, (1989)
  • [3] Buyse G., Waldeck K., Verpoorten C., Et al., Intravesical oxybutynin for neurogenic bladder dysfunction: Less systemic side effects due to reduced first pass metabolism, J Urol, 160, pp. 532-534, (1998)
  • [4] Chapple C.R., Muscarinic antagonists in the treatment of overactive bladder, Urology, 55, SUPPL. 5A, pp. 33-46, (2000)
  • [5] De Wachter S., Wyndaele J.J., Intravesical oxybutynin: A local anesthetic effect on bladder C afferents, J Urol, 169, pp. 1892-1895, (2003)
  • [6] Dinis P., Silva J., Ribeiro M.J., Et al., Bladder Cfiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS: A pilot study, Eur Urol, 46, pp. 88-93, (2004)
  • [7] Enzelsberger H., Schatten C., Kurz C., Comparison of emepronium bromide with intravesical administration of lidocaine gel in women with urge incontinence, Geburtshilfe Frauenheilkd, 51, pp. 54-57, (1991)
  • [8] Enzelsberger H., Helmer H., Kurz C.H., Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: A randomised trial, Br J Obstet Gynaecol, 102, pp. 929-930, (1995)
  • [9] Evans R.J., Intravesical therapy for overactive bladder, Curr Urol Rep, 6, pp. 429-433, (2005)
  • [10] Fowler C.J., Jewkes D., McDonald W.I., Et al., Intravesical capsaicin for neurogenic bladder dysfunction, Lancet, 339, (1992)